Overview

A class action lawsuit has been filed against Caribou Bioscienses, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU) and certain of the Company’s current and former senior executive officers alleging violations of the federal securities laws.  The Caribou class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Caribou securities between July 14, 2023, and July 16, 2024, both dates inclusive (the “Class Period”).  Investors have until February 24, 2025, to seek appointment as lead plaintiff in the Caribou class action lawsuit.

Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.  The Company’s pipeline includes allogeneic, or “off-the-shelf,” cell therapies from its chimeric antigen receptor-T (“CAR-T”) cell and chimeric antigen receptor -natural killer (“CAR-NK”) cell platforms.  Allogeneic cell therapies are referred to as “off-the-shelf” because they use cells that have already been collected from a donor, and which were modified, multiplied, and stored in a facility, before being infused into a patient.  According to the Company, this affords allogeneic cell therapies numerous advantages over their autologous counterparts, which rely on extracting, modifying, and multiplying a patient’s own cells before being infused back into that same patient.  Caribou’s lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that the Company is evaluating in patients with, inter alia, relapsed or refractory large B cell non-Hodgkin lymphoma (“r/r B-NHL”) in the Company’s ongoing ANTLER Phase 1 clinical trial, with a focus on second-line large B cell lymphoma (“LBCL”).

The Caribou class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) they had overstated CB-010’s safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (2) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; (3) all the foregoing was likely to have a significant negative impact on Caribou’s business and operations; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired Caribou securities between July 14, 2023, and July 16, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Caribou class action lawsuit is February 24, 2025.